Nature Communications (Jan 2017)
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
- Florencia Cayrol,
- Pannee Praditsuktavorn,
- Tharu M. Fernando,
- Nicholas Kwiatkowski,
- Rosella Marullo,
- M. Nieves Calvo-Vidal,
- Jude Phillip,
- Benet Pera,
- Shao Ning Yang,
- Kaipol Takpradit,
- Lidia Roman,
- Marcello Gaudiano,
- Ramona Crescenzo,
- Jia Ruan,
- Giorgio Inghirami,
- Tinghu Zhang,
- Graciela Cremaschi,
- Nathanael S. Gray,
- Leandro Cerchietti
Affiliations
- Florencia Cayrol
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Pannee Praditsuktavorn
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Tharu M. Fernando
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Nicholas Kwiatkowski
- Department of Cancer Biology, Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School
- Rosella Marullo
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- M. Nieves Calvo-Vidal
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Jude Phillip
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Benet Pera
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Shao Ning Yang
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Kaipol Takpradit
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Lidia Roman
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Marcello Gaudiano
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Ramona Crescenzo
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Jia Ruan
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- Giorgio Inghirami
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Tinghu Zhang
- Department of Cancer Biology, Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School
- Graciela Cremaschi
- Neuroimmunomodulation and Molecular Oncology Department, Institute for Biomedical Research (BIOMED), National Research Council of Argentina (CONICET), Catholic University of Argentina (UCA)
- Nathanael S. Gray
- Department of Cancer Biology, Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School
- Leandro Cerchietti
- Department of Medicine, Hematology and Oncology Division, Weill Cornell Medicine
- DOI
- https://doi.org/10.1038/ncomms14290
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
T-cell lymphomas are aggressive diseases associated with poor outcome. Here, the authors show that the THZ1, a CDK7 inhibitor, suppresses STAT transcriptional activity leading to apoptosis and sensitization to BCL2 inhibitors in T-cell lymphomas.
